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Abstract
Background: DNA methylation is an epigenetic phenomenon known to play an important role in
the development of cancers, including colorectal cancer (CRC). Aberrant methylation of promoter
regions of genes is potentially reversible, and if methylation is important for cancer survival,
demethylation should do the opposite. To test this we have addressed the hypothesis that DNA
methyltransferase inhibitors (DNMTi), decytabine and zebularine, potentiate inhibitory effects of
classical anti-CRC cytostatics, oxaliplatin and 5-fluorouracil (5-FU), on survival of CRC cells in vitro.
Results: Isobole and median effect analysis revealed that decytabine shows potent synergistic
interaction with oxaliplatin and 5-FU and that this is probably not the class effect of DNMTi as
zebularine shows strong antagonistic interaction with oxaliplatin. The synergistic combination
treatment was also applied to the cultures to investigate their mechanisms of action. We have
shown that combinations of decytabine with cytostatics produced dose-dependent growth
inhibition and treatment-induced apoptosis.
Conclusion:  The observed synergism between decytabine and cytostatics is most probably
related to the augmented apoptotic signal and allowed for significant (both biologically and
statistically) reduction of the cytotoxic doses of cytostatics used.
Background
Altered patterns of 5-cytosine methylation at CpG islands
located in the promoter regions of genes are implicated in
the development of a wide range of human cancers. This
change in DNA methylation may cause the transcriptional
silencing of important cancer-controlling genes such as
tumor suppressors and caretaker genes. Examples include
genes encoding: RB in retinoblastoma [1]; VHL in renal
carcinoma [2]; p15 in gliomas and leukemias [3]; BRCA1
in breast cancer [4]; E-cadherin  in hepatocellular carci-
noma, breast cancer, and prostate cancer [5]; GSTP1 in
prostate, breast, and renal cancer [6]; and p16INK4a in vir-
tually all human cancers studied including colorectal car-
cinoma (CRC) [7]. In colorectal carcinoma (CRC)
aberrant DNA methylation may be linked to the causal
mechanism in colon carcinogenesis [8]. Recently, it was
reported that aberrant methylation of promoter regions of
genes as p15, p16INK4a, estrogen receptor, MLH1 and APC
– all probably involved in the development of CRC is
potentially reversible [9] and therefore may constitute the
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target for demethylating agents. Therefore, reversal of
methylation by demethylating agents should lead to the
inhibition of cancer. If this hypothesis is correct such
agents should inhibit the survival of CRC cells in vitro.
However, it seems pointless to study the effects of
demethylating agents alone without combination with 5-
fluorouracil (5-FU) and/or oxaliplatin that are used for
CRC in the clinics as these cytostatics represent the back-
bone of the treatment of patients with CRC.
The question arises, therefore, whether the effect of com-
bined treatment (demethylating agents with cytostatics) is
superior to the treatment with each agent alone. To
address this question we evaluated the effects of demeth-
ylating agents, decytabine and zebularine, in combination
with cytostatics, oxaliplatin and 5-FU, on growth of cells
of Colo-205 human CRC cell line. The aim of the study
was to find out whether combinations of studied agents
produced additive, antagonistic or synergistic interaction
and in this way to set the stage for testing the drug combi-
nations in in vivo conditions. The obtained results indicate
that decytabine (but not zebularine) induced potent syn-
ergistic interaction with both studied cytostatics increas-
ing their cytotoxicity at lower doses.
Materials and methods
Cell culture and drug treatment
As a model of colon cancer cells, the Colo-205 human
colorectal cancer cell line, obtained from American Type
Culture Collection (ATCC, Manassas, VA, USA) was used.
The cells were cultured in RPMI 1640 medium (Gibco,
Paisley, UK) supplemented with 5% (v/v) heat-inacti-
vated fetal bovine serum (FBS, Gibco), 2 mM glutamax
(Gibco), 100 units/ml penicillin, 100 μg/ml streptomycin
and 250 ng/ml amphoterycin (Gibco) at 37°C in a
humidified atmosphere including 5% CO2. Cells were
incubated with drugs for 48 and 72 h. Both floating and
attached cells were harvested for subsequent analysis.
Drugs
The following drugs were studied: 5-fluorouracil (5-FU),
oxaliplatin, zebularine, decytabine (Sigma, St. Louis, MI,
USA). The concentrations of studied drugs were in the
range from 1 to 200 μM. The drugs were dissolved in
100% dimethylsulfoxide (DMSO, Sigma) and then
diluted in the media for experiments. The final concentra-
tion of DMSO, without effect on cell survival, was main-
tained at 0.2%. In all experiments control cells were
incubated with DMSO.
MTT assay
This assay relies on the ability of viable cells to metaboli-
cally reduce a yellow tetrazolium salt ([3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyl tetrazolium bromide], MTT
(Sigma) to purple formazan product via mitochondrial
dehydrogenase activity. Cells were grown in 96-well plates
(1 × 104 cells/200  μl/well). After incubation with the
drugs, the medium was removed and the cells were treated
with 50 μl of MTT for 4 h at 37°C. Next, 150 μl of solubi-
lization solution (10% SDS) were added and the mixture
was incubated at 37°C overnight. The solubilized forma-
zan product was spectrophotometrically quantified using
a microtiter plate reader, Power Wave XS (Bio-Tek,
Winooski, VT, USA), at 570 nm wavelength.
Drug interaction analysis
The nature of the interactions between studied drugs was
analyzed with the help of izobologram [10] and median
effect methods described by Chou and Talalay [11,12].
The Colo-205 cells were simultaneously incubated for 72
hours with combinations of either cytostatics (oxaliplatin
or 5-FU) with decytabine or zebularine or with each agent
alone. Isoboles were defined by effects of pair of studied
drugs. The effects obtained by IC50 of either drug in the
pair form the basis for the additivity line; synergism or
antagonism was present when the same effect was
obtained by the combination of drugs in lower or higher
doses, respectively [10].
The CI method is a mathematical and quantitative evalu-
ation of a two-drug pharmacologic interaction. Using data
from the cytotoxicity experiments and CalcuSyn ver. 2.0
software (Biosoft, Cambridge, UK), CI values were gener-
ated over a range of fractional cell kill levels (Fa) from
0.05 to 0.95 (5–95% cell kill). CIs of <1 indicated syner-
gism (the smaller the value, the greater the degree of syn-
ergy), CIs equal to 1 indicated additivity, and CIs>1
indicated antagonism. Data generated from the CI
method were used to quantify the dose-reduction index
(DRI) for the combination of two drugs. DRI represents
the fold-decrease of each individual agent when two drugs
are used in combination as opposed to alone to achieve a
particular Fa. Each CI or DRI ratio represented here is the
mean value derived from at least five independent experi-
ments
Flow cytometric analysis of cell cycle
Cells (~1 × 106) were resuspended in 4 ml of 80% ethanol
(- 20°C) and incubated at -20°C for 24 h, washed twice in
phosphate-buffered saline (PBS), and stained with 50 μg/
ml propidium iodide (PI) and 100 μg/ml RNase in 0.1%
PBST solution (PBS supplemented with 0.1% Triton ×
100) for 30 min in the dark at 4°C. The samples were then
measured using a BD FACSCalibure flow cytometer (BD
Biosciences, San Jose, CA, USA). The DNA histograms
were analyzed using ModFit software (BD Biosciences,
San Jose, CA, USA).
Flow cytometric analysis of apoptosis
Apoptosis was measured, according to the manufacturer's
instructions, using an annexin V-FITC kit (BD Biosciences,Cancer Cell International 2009, 9:10 http://www.cancerci.com/content/9/1/10
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San Jose, CA, USA). The cells were collected after treat-
ment, washed twice with PBS and centrifuged. The cell
pellet was resuspended in ice-cold binding buffer. The
annexin V-FITC and PI solutions were added to the cell
suspension and mixed gently. The samples were then
incubated for 15 min in the dark before flow cytometric
analysis.
Semi-quantitative RT-PCR
The mRNA levels of CCNE1,  ATM,  p53,  CASP3  and
GAPDH were analyzed by RT-PCR using total RNA from
Colo-205 cells isolated using the Total RNA Kit (Kucharc-
zyk TE, Warsaw, Poland), as described by the manufac-
turer. One hundred ng of total RNA was used in the
reverse transcription reaction with Omniscript Reverse
Transcriptase (Qiagen, Hilden, Germany) and oligo
(dT)18 primer (Fermentas, Vilnius, Lithuania). The PCR
amplifications were performed in a 50 μl total volume
according to manufacture's instruction using HotStarTaq
Master Mix (Qiagen), 3 μl of cDNA as a template and the
following primers pairs: CCNE1  (5'-AACTCAACGT-
GCAAGCCTCG-3'; 5'-CATCTCCTGAACAAGCTCCA-3'),
ATM (5'-GCCTT GAGTCTGTGTATTCG-3'; 5'-CCACTCA-
GAGACTCCACAGC-3'),  p53  (5'-GCTCTGAC TGTAC-
CACCATC-3'; 5'-CTTCTGACGCACACCTATTG-3'),
CASP3  (5'-CTGGACTG TGGCATTGAGAC-3'; 5'-
TGCAACTACCTGACTGGAAG-3') and GAPDH (5'-TCAC-
CATC TTCCAGGAGCGA-3'; 5'-TGGTCATGAGTCCTTC-
CACG-3'). The GAPDH mRNA levels were used as internal
controls. The amplified fragments were separated on 2%
agarose gels, stained with ethidium bromide, photo-
graphed under UV light.
Immunoblotting
The cells were washed with cold PBS buffer and then the
nuclear and cytoplasmic fractions were extracted using the
NE-PER extraction kit (Pierce, Rockford, IL, USA). Protein
concentration in the samples was measured using BCA
protein assay kit (Pierce, Rockford, IL, USA). Samples con-
taining 30 μg of protein were denatured and fractionated
by 12% SDS-PAGE. After electrophoresis, the proteins
were transferred to a nitrocellulose membrane and
probed with anti-human antibodies specific to: cyclin A1,
D1 and PARP (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA); p21, pro-caspase 8 (BD Biosciences,
Pharmingen, Poland); pro-caspase 3, β-actin (Sigma,
Poland). The signal was detected by a colorimetric
method using the Opti-Amplified Immun-blot Assay kit
(Bio-Rad, Hercules, CA, USA).
Mitochondrial membrane potential (ΔΨm) measurement
ΔΨm was measured using MitoLight™ Apoptosis Detection
Kit (Chemicon Int., Germany). Cells were treated with
decytabine and cytostatics or their combinations for 48 h,
stained according to the kit producer's protocol and exam-
ined by Olympus IX70 FV500 confocal microscope. The
dye was excited with Ar-blue 488 nm laser. The fluores-
cence of monomer and aggregates of the dye were
detected using 505–525 nm and 560–620 nm bandpass
filters respectively. MitoLight (5,5',6,6'-tetrachloro-
1,1',3,3'-tetraethylbenzimidazolylcarbo-cyanine chloride
a mitochondrial dye included in the kit, stains mitochon-
dria in living cells. In healthy cells, the dye accumulates in
mitochondria, forming aggregates that emit red fluores-
cence, while in apoptotic cells the dye remains in cyto-
plasm and emits green fluorescence. [13].
Statistical analysis
Data were presented as mean values ± SD (standard devi-
ation). Statistical comparisons among groups were per-
formed by Student's t-test or one-way analysis of variance
(ANOVA) followed by Tukey post hoc test. Significance
was assumed at p < 0.05 (marked with asterisks).
Results
Growth studies
The studied drugs, used in the concentration range from
3.75 to 100 μM, inhibited the survival of Colo-205 cells in
vitro. Among tested compounds that were incubated with
Colo-205 cells for 48 and 72 hours oxaliplatin and 5-FU
showed the most potent inhibition of Colo-205 cells
growth with the maximum following 72 hours incubation
time (Fig. 1). The inhibitory effects of cytostatics were
dose dependent and the correlation coefficients (esti-
mated from the inhibitory dose-response curves) were
above 0.9. Demethylating agents, decytabine and zebular-
ine, have demonstrated different mode of inhibition:
decytabine was already inhibitory at low concentrations
(starting from 7.5 μM), whereas zebularine showed non-
significant stimulation of Colo-205 cells growth at low
concentration and was inhibitory, starting from concen-
trations of 45 μM.
The effects of various combinations of cytostatics with
demethylating agents (decytabine and zebularine) on
CRC cells survival are shown also in Fig. 1. Decytabine,
from concentration of 7.5 μM up to 60 μM potentiated the
inhibitory effects of oxaliplatin and in concentration from
7.5 μM to 30 μM potentiated the inhibitory effect of 5-FU
on survival of CRC cells whereas zebularine, tested at con-
centrations up to 60 μM did not potentiate inhibitory
effects of either cytostatic studied (Fig. 1).
Interactions of cytostatics with decytabine or zebularine
The results of various combinations of decytabine and
zebularine with cytostatics (oxaliplatin and 5-FU) on
Colo-205 cells were analyzed with the help of isobolo-
grams and median effects method of Chou and Talalay.
Isobolograms indicated that interaction of decytabine
with oxaliplatin or 5-FU resulted in strong synergistic
interaction, whereas combination of zebularine with cyto-
statics produced different results; zebularine antagonizedCancer Cell International 2009, 9:10 http://www.cancerci.com/content/9/1/10
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inhibitory effect of oxaliplatin on survival of CRC cells
(Fig. 2) and was without influence (only additive interac-
tion was observed) on effect of 5-FU.
Analysis performed with the help of median effect
method (Table 1) revealed that combination of decytab-
ine and cytostatics produced synergistic effects at all of
three (25%, 50% and 75%) Fa levels achieving CI (Com-
bination Index) values of ≤ 0.29 and ≤ 0.68 for oxaliplatin
and 5-FU, respectively. Combination of the zebularine
and cytostatics in the range of Fa ≥ 0.5 (50%) produced
only antagonistic or additive effects.
The dose reduction index (DRI) indicated that the pres-
ence of decytabine allowed for 4.3-fold reduction of IC50
dose in the case of oxaliplatin and 3.4-fold reduction in
the case of 5-FU (Table 1). The dose-reduction effects for
combinations of zebularine with cytostatics were not eval-
uated because these combinations did not show synergis-
tic effects.
Effect of combined treatment with cytostatics and 
demethylating agents on cell cycle progression and 
induction of apoptosis
In the control culture, the percent of cells in each phase
was stable. The tested compounds had exerted various
effects on the cell cycle and apoptosis. Treatment with
cytostatics resulted in a consistent increase of number of
cells in the S phase at the expense of G1 phase. Decytabine
alone arrested the cell cycle in the G2/M phase, whereas
the effect of zebularine on CRC cell cycle was negligible.
Combination of decytabine with oxaliplatin or 5-FU as
compared with oxaliplatin or 5-FU alone, induced cell
cycle arrest in the S phase and the G1/S phase, respectively
(Fig. 3). Combination of zebularine with oxaliplatin, as
compared to oxaliplatin alone, increased the number of
cells in the G2/M phase and decreased the number of cells
in the S phase (Fig. 3), whereas combination of zebularine
with 5-FU exerted the same effect as 5-FU alone (Fig. 3).
Analysis of genes expression revealed that combination of
decytabine with 5-FU, as compared with 5-FU alone,
increased mRNA levels of: CCNE1 (a gene encoding cyclin
E1), ATM, p53, and CASP3 (a gene encoding pro-caspase
3) (Fig. 4A). Analysis of proteins specific for cell cycle pro-
gression revealed that combination of decytabine with 5-
FU, as compared with 5-FU alone, increased levels of cyc-
lin A1 and decreased levels of cyclin D1 and p21 (Fig. 4B).
Analysis of genes expression revealed that combination of
decytabine with oxaliplatin, as compared to oxaliplatin
alone, increased mRNA level of ATM. Analysis of proteins
specific for cell cycle progression revealed that combina-
tion of decytabine with oxaliplatin, as compared with
oxaliplatin alone, increased level of cyclin A1 and
decreased level of cyclin D1 (Fig. 4B).
Treatment of CRC cells with oxaliplatin or 5-FU alone
induced apoptosis in ~40% of the cells. The percentage of
apoptotic cells increased when cells were coincubated
with decytabine: to 60% in the case of oxaliplatin and to
~55% in the case of 5-FU (Fig. 5). Combination of zebu-
larine with oxaliplatine did not increase apoptosis
whereas combination with 5-FU increased significantly
the number of apoptotic CRC cells.
In addition, induction of apoptosis in the Colo-205 cells
induced by combination of cytostatics with decytabine
increased levels of mRNA of CASP3 gene and pro-caspase
3 and 8 proteins, as compared with the control. The pro-
teolytic cleavage of the poly (ADP-ribose) polymerase
Effect of combination treatment with cytostatics and DNMTi  agents on survival of the Colo-205 cells Figure 1
Effect of combination treatment with cytostatics and 
DNMTi agents on survival of the Colo-205 cells. 
Human colorectal cancer cells were exposed to 5-fluorour-
acil (5-FU) (A) or oxaliplatin (B) with and without demethyl-
ating agents, decytabine and zebularine (concentrations, in 
μM, below figures) for 72 h. Each bar represents the mean ± 
SD (n = 5), asterisks indicates significance at p < 0.05, for 
comparison with 5-FU or oxaliplatin.
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Interaction of cytostatics with decytabine and zebularine Figure 2
Interaction of cytostatics with decytabine and zebularine. Concentrations (μM) of particular drugs are indicated on x 
and y axis. The isobolograms were constructed by connecting the IC50 values of demethylating agents (on the ordinate) with 
the IC50 of oxaliplatin or 5-FU plotted on the abscissa. When the doses of two agents in combination are lower, or higher, than 
additive doses, the synergy or antagonism, respectively, is present.
Table 1: Combination index (CI) and dose reduction index (DRI) values for drugs combinations schedule after 72 h of simultaneous 
treatment.
Drugs Molar 
ratio
CI ± SD at Fraction affected 
level
DRI ± SD at Fraction affected level
25% 50% 75% 25% 50% 75%
I I I I + I II + I II + I I I I I I I I I I I
5-FU Decytabine 1.7:1 0.25 ± 0.1* 0.36 ± 0.1* 0.63 ± 0.3* 6.38 ± 1.9* 12.8 ± 5* 3.4 ± 0.7* 14.1 ± 3.1* 2.3 ± 0.6* 22.7 ± 9
Zebularine 1.7:1 1.24 ± 0.2 0.76 ± 0.1* 0.68 ± 0.1 N/D N/D 1.9 ± 0.7* 4.6 ± 1.8* 4.1 ± 2 2.2 ± 0.5*
Oxaliplatin Decytabine 1:2 0.28 ± 0.1* 0.17 ± 0.1* 0.12 ± 0.1* 0.83 ± 0.4* 1.4 ± 0.4* 4.3 ± 0.43* 12.2 ± 3.1 N/A N/A
Zebularine 1:2 0.29 ± 0.3* 2.90 ± 0.5* N/A 0.47 ± 0.3 1.3 ± 0.7 N/D N/D N/D N/D
Data are expressed as means ± SD (n = 8 for CI; n ≥ 3 for DRI). *, p < 0.05; N/D, not determined; N/A, not achieved at the highest concentration 
tested. A CI value significantly less than 1 indicates synergy, a CI not significantly different from 1 indicates addition, and a CI significantly higher than 
1 indicates antagonism. The DRI determines the magnitude of dose reduction allowed for each drug when given in synergistic combination, as 
compared with the concentration of a single agent that is needed to achieve the same effect. 25, 50 and 75% indicates selected values of fraction 
affected level.Cancer Cell International 2009, 9:10 http://www.cancerci.com/content/9/1/10
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(PARP) was augmented following incubation of cells with
cytostatics and decytabine (Fig. 4B).
The changes in mitochondrial membrane potential (ΔΨm)
The ΔΨm was evaluated using potential-sensitive dye Mito-
Light. Cells, previously treated for 48 h with decytabine,
cytostatics or their combinations were loaded with the dye
and tested by the confocal microscope. The image analysis
revealed high polarization of control cells (Fig. 6).
Decytabine in a dose-dependent manner increased mem-
brane depolarization (green fluorescence) and further
depolarized cells when coincubated with studied cytostat-
ics. Combinations of decytabine with both cytostatics
caused an increase in green with concomitant decrease in
red fluorescence signals (Fig. 6)
Discussion
The important finding of the present work is the demon-
stration that DNA methyltransferase inhibitor (DNMTi),
decytabine, potentiated cytotoxic effects of classical cyto-
statics, 5-FU and oxaliplatin, in colorectal carcinoma
(CRC) cell line Colo-205. The second important finding is
that the potentiating effect of decytabine is probably not
the class effect of DNMT inhibitors, as the effect of zebu-
larine was qualitatively different.
DNMTi have recently gained attention as agents inhibit-
ing cancer growth including colorectal carcinoma [14].
However, the role of their therapeutic potential could be
properly evaluated only in combination with classical
agents used in the treatment of CRC, since all new thera-
peutic agents are introduced as add-on options. Since 5-
fluorouracil (5-FU) and oxaliplatin constitute the back-
bone treatment of CRC [15], we investigated the effects of
addition of decytabine or zebularine, methyltransferase
inhibitors (DNMTi), to oxaliplatin or 5-FU on survival of
Colo-205 human CRC cells in vitro.
We have found that studied agents, when given alone,
induced the inhibition of Colo-205 cancer cells growth in
vitro with comparable order of potency (estimated on the
basis of survived cells percent), with the exception of
zebularine that in low concentrations stimulated growth
of CRC cells and was inhibitory only above 45 μM (Fig. 1A
and 1B). When cancer cells were treated with the combi-
nation of agents, the addition of decytabine to oxaliplatin
or 5-FU increased inhibition of growth of cancer cells (Fig.
1A and 1B). The isobolograms, constructed on the basis of
IC50 values, indicated the synergistic interaction between
decytabine and both studied cytostatics, oxaliplatin and
5-FU, and the antagonism between zebularine and oxali-
platin (Fig. 2) and lack of any interaction between zebu-
larine and 5-FU, as only additive effect was observed.
Highly synergistic interaction resulting from addition of
decytabine to oxaliplatin and, to a lesser extent, to 5-FU
Combinations of cytostatics with DNMTi agents induced  changes in the cell cycle progression Figure 3
Combinations of cytostatics with DNMTi agents 
induced changes in the cell cycle progression. DNA 
histograms showing cell cycle phase distribution of Colo-205 
cells treated with demethylating agents, cytostatics and their 
combinations (in concentrations as indicated) for 72 h and 
determined by FACS analysis, as described in Materials and 
Methods. Flow cytometric profiles of DNA content upon PI 
staining from a representative experiment are shown. Per-
centages are given for each cell phase as mean ± SD (n = 4). 
Asterisks indicates significance at p < 0.05, for comparison 
with control.
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Effect of combinations of cytostatics with decytabine on the cell cycle and apoptosis regulators Figure 4
Effect of combinations of cytostatics with decytabine on the cell cycle and apoptosis regulators. (A), Analysis of 
CCNE1, ATM, p53 and CASP3 mRNA expression by semi-quantitative RT-PCR method after 72 h incubation of Colo-205 cells 
with cytostatics, decytabine and their combinations at concentrations as indicated. GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase – internal control. (B), Immunoblotting analysis of the level of pro-apoptotic and cell cycle regulatory proteins fol-
lowing 72 h incubation of colorectal cells with cytostatics (5-FU, oxaliplatin), decytabine and their combinations at indicated 
concentrations. A representative blot of 2–3 ones for each particular protein is shown. The β-actin was used as a gel loading 
control. (C), Comparison of the relative amount of pro-apoptotic and cell cycle regulatory proteins, in samples shown in panel 
B, estimated by blot scanning and quantification of band intensities with the QuantiScan ver. 3.0 (Biosoft, UK) densitometry 
analysis software. The protein levels were normalized according to the gel loading control (β-actin) and presented as a per-
centage of control (level of particular protein in untreated cells). For particular protein, two to three blots were analyzed (n = 
2 to 3). Each bar represents the mean ± SD; asterisks indicates significance at p < 0.05, for comparison with control.
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was quantitatively analyzed according to Chou and Tala-
lay method. The obtained Combination Index (CI) was in
the case of oxaliplatin and decytabine between 0.12–0.28
and in case of 5-FU and decytabine between 0.25–0.63 in
the broad range, 25% to 75%, of fraction affected (Fa)
level (Table 1). These ranges are regarded as "high syner-
gism" or "synergism" according to Peters and co-workers
[16].
The observed synergistic interaction between decytabine
and oxaliplatin was dose-dependent. The observed antag-
onism between zebularine and oxaliplatin on CRC cells
survival increased with the dose of zebularine. It appears,
therefore, that two methyltransferase inhibitors, belong-
ing to the same class of agents, influence the inhibitory
effects of cytostatics on CRC cells growth in a qualitatively
different manner. These differences could be related to the
direct effects of studied DNMTis on survival of CRC cells
since decytabine by itself induced inhibition of CRC cell
growth, whereas zebularine induced non-significant but
apparent stimulation of growth of CRC cells and inhibi-
tion only at higher concentrations (Fig. 1A and 1B). The
interaction between decytabine and both cytostatics was
paralleled by significant induction of apoptosis which was
higher in case of combination.
The strong synergism between decytabine and cytostatics
reported here could be explained by the ability of decytab-
ine to bind covalently with DNMT thus obstructing DNA
synthesis and in this way leading to the cell death.
Decytabine may also induce DNA damage through struc-
tural instability at the site of incorporation [17,18] with
the resulting activation of ATM kinase and consequently
p53 protein [19], what was confirmed in the present study
(Fig. 4).
The most powerful combination, decytabine and oxalipl-
atin, led to CRC cell cycle arrest in the S phase and, when
compared to the control cycle, strong reduction of cell
number in the G1 phase (Fig. 3). This was accompanied
by increased mRNA level of ATM, suggesting induction of
ATM-dependent pathway. Activation of this pathway may
lead to activation of Chk2 kinase which via phosphoryla-
tion of Cdc25A induces its degradation. The down regula-
tion of Cdc25A leads to inhibition of DNA synthesis and
cell cycle arrest of CRC cells in the S phase, a predominant
effect of decytabine and oxaliplatin combination (Fig. 3,
4). Moreover, the synergistic interaction between decytab-
ine and cytostatics led to augmentation of pro-caspase 3
and 8 levels in cytosolic fractions and mRNA level of p53
gene (Fig. 4). Thus, the cytotoxic effect of decytabine and
cytostatics, could result from apoptosis induced by inter-
nal and external signals. Indeed, the possible involvement
of mitochondrial pathway was indicated by the finding
that combination of decytabine with cytostatics induced
the disruption of ΔΨm  (Fig. 6). The combination of
decytabine and both cytostatics resulted in powerful
apoptotic signal that was manifested by fragmentation of
PARP protein into 84 kDa and 25 kDa fragments also
indicating apoptosis (Fig. 4).
In summary, we have demonstrated, for the first time, that
decytabine, DNMT inhibitor, exerted powerful synergistic
interaction with oxaliplatin and 5-FU, inhibiting the sur-
vival of CRC cells in vitro. In contrast, the influence of
other DNMTi, zebularine, on the inhibitory effect of oxali-
platin on survival of CRC cells was antagonistic. Thus, the
synergistic interaction of decytabine with cytostatics rep-
resenting the backbone treatment of CRC is probably not
the class effect of DNMTi.
The mechanism of synergism between decytabine and
oxaliplatine or 5-FU is probably related to the augmenta-
tion of apoptotic signal when compared with either agent
applied alone. Such augmentation may suggest that cyto-
toxic effects of classical cytostatics used in the treatment of
colorectal carcinoma, when combined with decytabine,
Effect of cytostatics and DNMTi agents combinations on  induction of apoptosis Figure 5
Effect of cytostatics and DNMTi agents combinations 
on induction of apoptosis. Percentage of apoptosis deter-
mined by FACS analysis, after 72 h treatment with demethyl-
ating agents, cytostatics and their combinations in 
concentrations as indicated. Each column represented of 
four independent experiments. The results are expressed as 
the mean ± SD. Induction of apoptosis by cytostatics and 
demethylating agents was significant in comparison with con-
trol; astericks denote p < 0.05 for combination of cytostatics 
and demethylating agents versus cytostatics alone.
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could be obtained at lower doses and with higher probabil-
ity to induce death of cancer cells. That is why the presented
results could be of interest for biologists and clinicians.
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Microscopic images of changes in mitochondrial membrane potential (ΔΨm) Figure 6
Microscopic images of changes in mitochondrial membrane potential (ΔΨm). Cells were incubated with cytostatics, 
decytabine or their combination for 48 h and examined by confocal microscopy to detect changes in the mitochondrial mem-
brane potential ΔΨm. Left image, detection of the monomers (green fluorescence) indicating the presence of depolarized mito-
chondria (apoptotic cells). Right image, detection of the aggregates (red fluorescence) indicating the functional, polarized 
mitochondria.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cancer Cell International 2009, 9:10 http://www.cancerci.com/content/9/1/10
Page 10 of 10
(page number not for citation purposes)
Authors' contributions
SF conceived of the study, designed, coordinated the
study, carried out the: proliferation, RT-PCR and flow
cytometry assays, interaction and statistical analysis and
drafted the manuscript; AG carried out the proliferation
and western blotting assays; IM worked as an confocal
microscopy specialist for the examination of the samples;
JS revised the manuscript critically for important intellec-
tual content and helped draft the manuscript.
Acknowledgements
Authors also would like to thanks Polpharma S.A. for financial support.
References
1. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T:
CpG methylation inactivates the promoter activity of the
human retinoblastoma tumor-suppressor gene.  Oncogene
1993, 8:1063-1067.
2. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan
DS, Gnarra JR, Linehan WM: Silencing of the VHL tumor-sup-
pressor gene by DNA methylation in renal carcinoma.  Proc
Natl Acad Sci USA 1994, 91:9700-9704.
3. Herman JG, Jen J, Merlo A, Baylin SB: Hypermethylation-associ-
ated inactivation indicates a tumor suppressor role for
p15INK4b.  Cancer Res 1996, 56:722-727.
4. Mancini DN, Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM,
Xing W, Archer TK: CpG methylation within the 59 regulatory
regions of the BRCA1 gene is tumor specific and includes a
putative CREB binding site.  Oncogene 1998, 16:1161-1169.
5. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M, Hiro-
hashi S: The E-cadherin gene is silenced by CpG methylation
in human hepatocellular carcinomas.  Int J Cancer 1997,
71:355-359.
6. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG:
Inactivation of glutathione S-transferase P1 gene by pro-
moter hypermethylation in human neoplasia.  Cancer Res 1998,
58:4515-4518.
7. Myohanen SK, Baylin SB, Herman JG: Hypermethylation can
selectively silence individual p16INK4a alleles in neoplasia.
Cancer Res 1998, 58:591-593.
8. Grady WM: Epigenetic events in the colorectum and in colon
cancer.  Biochem Soc Tran 2005, 33:684-688.
9. Cormier RT, Dove WF: Dnmt1N/+ reduces the net growth rate
and multiplicity of intestinal adenomas in C57BL/6-multiple
intestinal neoplasia (Min)/+ mice independently of p53 but
demonstrates strong synergy with the modifier of Min
1(AKR) resistance allele.  Cancer Res 2000, 60:3965-3970.
10. Gessner PK: Isobolographic analysis of interactions: an update
on applications and utility.  Toxicology 1995, 105:161-179.
11. Chou TC, Talalay P: Quantitative analysis of dose-effect rela-
tionships: the combined effects of multiple drugs or enzyme
inhibitors.  Adv Enzyme Regul 1984, 22:27-55.
12. Chou TC, Talalay P: Analysis of combined drug effects: A new
look at a very old problem.  Trends Pharmacol Sci 1983, 4:450-454.
13. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW,
Steele GD Jr, Chen LB: Intracellular heterogeneity in mito-
chondrial membrane potentials revealed by a J-aggregate-
forming lipophilic cation JC-1.  Proc Natl Acad Sci 1991,
88:3671-3675.
14. Hellebrekers DM, Griffioen AW, van Engeland M: Dual targeting of
epigenetic therapy in cancer.  BBA 2007, 1775:76-91.
15. Chau I, Cunningham D: Adjuvant therapy in colon cancer–what,
when and how?  Ann Oncol 2006, 17:1347-59.
16. Peters GJ, Wilt CL Van Der, Van Moorsel CJA, Kroep JR, Bergman
AM, Ackland SP: Basis for effective combination cancer chem-
otherapy with antimetabolites.  Pharmacol Therapeut 2000,
87:227-253.
17. Goffin J, Eisenhauer E: DNA methyltransferase inhibitors–state
of the art.  Ann Oncol 2002, 13:1699-1716.
18. Palii S, Van Emburgh B, Sankpal U, Brown K, Robertson K: Methyla-
tion Inhibitor 5-Aza-2'-Deoxycytidine Induces Reversible
Genome-Wide DNA Damage That Is Distinctly Influenced
by DNA Methyltransferases 1 and 3B.  Mol Cell Biol 2008,
28:752-771.
19. Kurz EU, Lees-Miller SP: DNA damage-indiuced activation of
ATM and ATM-dependent signaling pathways.  DNA Repair
2004, 3:889-900.